7 terminated, 6 completed, 5 withdrawn, 2 active not recruiting. 22 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Terminated 7, Completed 6, Withdrawn 5, Active not recruiting 2, Unknown 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Hypothalamic Neoplasms: new trials by email Literature Review of Hypothalamic Neoplasms trials Research Report on Hypothalamic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo - Hypothalamic Obesity, Hypothalamic Tumor | Phase 2 | Active not recruiting | Seattle Children's Hospital | 24 | 2025-03-01 | 2026-10-16 |
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery Tranexamic acid, Placebo - Pituitary Tumor, Blood Loss | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2022-03-01 | 2022-04-05 | |
| TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas TBR-760, Placebo - Non-Functional Pituitary Adenoma, Pituitary Tumor, Nonfunctioning | Phase 2 | Unknown | Tiburio Therapeutics | 150 | 2020-05-01 | 2020-04-06 |
| The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas Radiotherapy plus temozolomide, Radiotherapy plus placebo - Pituitary Adenomas | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 150 | 2020-02-10 | 2020-01-28 |
| Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors Ipilimumab, Nivolumab - Pituitary, Pituitary Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 10 | 2019-07-31 | 2026-06-02 |
| Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers Lutetium Lu 177 Dotatate - Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-06-13 | 2020-09-07 | |
| Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Capecitabine, Temozolomide - Recurrent Pituitary Adenomas | Phase 2 | Terminated | Weill Medical College of Cornell University | 1 | 2019-05-21 | 2022-08-09 |
| Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Pasireotide LAR - Pituitary Tumor, ACTH-producing Pituitary Tumour | Phase 2 | Terminated | Columbia University | 4 | 2017-07-10 | 2021-04-27 |
| Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Photofrin photodynamic therapy. - Brain Tumor, Recurrent | Phase 2 | Terminated | Harry T Whelan, MD | 1 | 2015-06-01 | 2019-08-20 |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 68 | 2014-03-06 | 2020-09-18 |
| Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy Radiation according to indication with hippocampal sparing, Radiation according to indication without hippocampal protection - Radiation of Neurocranial Region | Phase 2 | Active not recruiting | University of Erlangen-Nürnberg Medical School | 150 | 2013-03-01 | 2026-10-27 |
| Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism Pasireotide LAR - Acromegaly, Pituitary Gigantism | Phase 2 | Completed | Novartis Pharmaceuticals | 33 | 2012-10-16 | 2019-09-16 |
| Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Farletuzumab - Resectable, Non-functioning Pituitary Adenoma | Phase 2 | Withdrawn | Morphotek | 2011-02-01 | 2013-11-04 | |
| Temozolomide in Treating Patients With Invasive Pituitary Tumors temozolomide, DNA methylation analysis, microarray analysis - Brain and Central Nervous System Tumors | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2009-12-01 | 2020-07-31 | |
| Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin pasireotide LAR - Pancreatic Neoplasm, Pituitary Neoplasm | Phase 2 | Terminated | Novartis Pharmaceuticals | 118 | 2009-09-01 | 2016-07-26 |
| Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Lapatinib - Pituitary Adenomas, Prolactinomas | Phase 2 | Completed | Cedars-Sinai Medical Center | 9 | 2009-07-01 | 2020-01-22 |
| Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas pasireotide LAR - Gonadotroph Adenomas | Phase 2 | Terminated | University of Pennsylvania | 2 | 2009-06-01 | 2017-11-28 |
| Rosiglitazone in Treating Patients With Pituitary Tumors rosiglitazone maleate - Brain and Central Nervous System Tumors | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 1 | 2006-10-01 | 2020-08-14 |
| Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities TRH (Thyrotropin Releasing Hormone) - Healthy, Pituitary Disease | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 96 | 2003-02-07 | 2018-08-08 |
| Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Technetium Tc 99m EC20 - Pituitary Tumors | Phase 2 | Completed | Endocyte | 40 | 2002-09-01 | 2023-06-22 |
Showing 20 of 22. Sign in to see all of them.
Pituitary Neoplasms (21) · Acromegaly (2) · Brain Neoplasms (2) · Central Nervous System Neoplasms (2) · Craniopharyngioma (2) · Growth Hormone-Secreting Pituitary Adenoma (2) · Meningioma (2) · Pituitary Diseases (2) · Prolactinoma (2) · ACTH Syndrome, Ectopic (1) · Adenoma, Acidophil (1) · Adenoma, Basophil (1) · Adenoma, Chromophobe (1) · Adrenocortical Hyperfunction (1) · Astrocytoma (1)
Brain Diseases (22) · Central Nervous System Diseases (22) · Endocrine System Diseases (22) · Hypothalamic Diseases (22) · Neoplasms (22) · Neoplasms by Site (22) · Nervous System Diseases (22) · Nervous System Neoplasms (22) · Supratentorial Neoplasms (22) · Endocrine Gland Neoplasms (21) · Brain Neoplasms (20) · Central Nervous System Neoplasms (20) · Pituitary Diseases (19) · Neoplasms by Histologic Type (8)
pasireotide (4) · Temozolomide (3) · Biological Therapy (1) · Cabergoline (1) · Capecitabine (1) · Complementary Therapies (1) · DNA Methylation (1) · Ipilimumab (1) · Lapatinib (1) · Microarray Analysis (1) · Nivolumab (1) · Phentermine (1) · Qsymia (1) · Radiotherapy (1) · Rosiglitazone (1)
Novartis Pharmaceuticals (3) · Jonsson Comprehensive Cancer Center (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Burzynski Research Institute (1) · Cedars-Sinai Medical Center (1) · Columbia University (1) · Endocyte (1) · Harry T Whelan, MD (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Morphotek (1) · Peking Union Medical College Hospital (1) · Seattle Children's Hospital (1) · Tiburio Therapeutics (1) · University of Erlangen-Nürnberg Medical School (1)
United States (16) · Germany (3) · Argentina (2) · Brazil (2) · France (2) · Italy (2) · Mexico (2) · Spain (2) · Australia (1) · Belgium (1) · Canada (1) · Colombia (1) · Greece (1) · Hungary (1) · India (1)
Anthony Heaney, MD (2) · Andrew Lin, MD (1) · Brent Senior, MD (1) · Bruce Wallin, MD (1) · Camilo Jimenez (1) · Christian L Roth, MD (1) · Harry T Whelan, MD (1) · Joanna Klubo-Gwiezdzinska, M.D. (1) · Nelson Oyesiku, MD (1) · Nelson Oyesiku, MD, PhD, FACS (1) · Odelia Cooper, MD (1) · Pamela Freda, MD (1) · Peter J. Snyder, MD (1) · Rainer Fietkau, MD (1)
PMID 33150390, PMID 33362722, PMID 35954244, PMID 36856733, PMID 37876540
2008 (1)